Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amgen (AMGN)

Amgen Q1 2026 revenue rises 6% to $8.6 billion; non-GAAP EPS up 5% to $5.15

Positive Impact 3 of 5 earnings Written later

Amgen reported first-quarter 2026 results on April 30, 2026, with total revenues up 6% to $8.6 billion and non-GAAP EPS up 5% to $5.15. Sales of Prolia and Enbrel declined, and the company issued full-year 2026 revenue and EPS ranges. The filing also discloses an FDA proposal to withdraw approval of TAVNEOS, which the company says will remain on the market during the review.

Key points

  • Total revenues rose 6% to $8.6 billion in the first quarter of 2026 versus the first quarter of 2025.
  • GAAP EPS rose 4% to $3.34 from $3.20; non-GAAP EPS rose 5% to $5.15 from $4.90.
  • 2026 guidance: total revenues of $37.1 billion to $38.5 billion and non-GAAP EPS of $21.70 to $23.10.
  • On April 27, 2026, the FDA proposed withdrawing approval of TAVNEOS, which had $119 million of first-quarter sales.

The filing

CompanyAmgen (AMGN)
Form8-K, current report
Filed with the SECApr 30, 2026, 4:03 PM ET
Accession number0000318154-26-000054

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.